3月25日,默沙东与恒瑞医药签署了新一代降脂药物的许可协议,潜在交易规模达20亿美元。该药物为一款口服小分子脂蛋白(a) (也称Lp(a)) 抑制剂,脂蛋白(a)也是近年来心血管药物研发的热门赛道,目前全球范围内尚无相关产品上市。 恒瑞的这款药物目前正在中国进行二期临床试验。默沙东将获得该药物在大中华区以外的全球范围内开发、生产和商业化的独家权利。 就在去年10月,阿斯利康也宣布与石药集团达成...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.